Pharmacological Therapies in Alzheimer's Disease

Principles and Practice of Geriatric Psychiatry: Third Edition

Volumn , Issue , 2010, Pages 304-311

  Steinberg, Martin ^a   Lyketsos, Constantine G ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease (AD), progressive neurodegenerative disorder deterioration in cognition and functioning, and neuropsychiatric co morbidity; Cognition and function deterioration and neuronal system degeneration; Common and less common side effects of cholinesterase inhibitors and memantine; Donepezil and oral rivastigmine in treatment of mild to moderate AD; Galantamine, FDA approved in 2001 treatment of mild to moderately severe AD; Memantine trial, in patients with moderate to severe AD; Neuropsychiatric effects of cholinesterase inhibitors and memantine; Pharmacological therapies in Alzheimer's disease; Side effects of galantamine identical to those of donepezil; Switching acetylcholinesterase inhibitors

Indexed keywords

EID: 84885761170     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470669600.ch52     Document Type: Chapter

References (47)

1. Rabins PV, Lyketsos CG, Steele CD. Practical Dementia Care. Oxford: Oxford University Press, 2006.
2. Farlow MR, Boustani M. Pharmacologic treatment of Alzheimer disease and mild cognitive impairment. In Weiner MF, Lipton AM (eds), The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias. Arlington, VA: American Psychiatric Publishing, 2009, 317-31.
3. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31.
4. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
5. Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58: 427-33.
6. Tariot P, Cummings JL Katz IR et al. A randomized, doubleblind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
7. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003; 51: 937-44.
8. Wimo A, Winblad B, Shah SN et al. Impact of donepezil treatment for Alzheimer's disease on caregiver time. Curr Med Res Opin 2004; 20: 1221-5.
9. Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15.
10. Winblad B, Wimo A, Engedal K et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006; 21: 353-63.
11. Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367: 1057-65.
12. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
13. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1-7.
14. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least months: a long-term extension trial. Arch Neurol 2004; 61: 252-6.
15. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-8.
16. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. In J Psychopharmacol 1998; 2: 55-65.
17. Figiel GS, Koumaras B, Meng X, Strigas J, Gunay I. Longterm safety and tolerability of rivastigmine in patients with Alzheimer's disease switched from donepezil: an open-label extension study. Prim Care Companion J Clin Psychiatry 2008; 10: 363-7.
18. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005; 59: 473-7.
19. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother 2007; 11: 1457-63.
20. Wilkinson DG, Passmore AP, Bullock R et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002; 56: 441-6.
21. Bullock R, Touchon J, Bergman H et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-27.
22. Wilcock G, Howe I, Coles H et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 2003; 20: 777-89.
23. Figiel GS, Sadowsky CH, Strigas J et al. Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. Prim Care Companion J Clin Psychiatry 2008; 10: 291-8.
24. Bartorelli L, Giraldi C, Saccardo M et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease. Curr Med Res Opin 2005; 21: 1809-18.
25. Singh B, O'Brien JT. When should drug treatment be started for people with dementia? Maturitas 2009; 62: 230-4.
26. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 2006; 3: CD006104.
27. Homma A, Imai Y, Tago H et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord 2009; 27: 232-9.
28. Reisberg B, Doody R, Stoffler A et al. Memantine in moderateto- severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
29. Bullock R. Efficacy and safety of memantine in moderate-tosevere Alzheimer disease: the evidence to date. Alzheimer Dis Assoc Disord 2006; 20: 23-9.
30. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006; 63: 49-54.
31. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
32. Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7.
33. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; MemantineMEM- MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebocontrolled trial. Curr Alzheimer Res 2008; 5: 83-9.
34. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214-9.
35. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161: 532-8.
36. Cummings JL, Koumaras B, Chen M, Mirski D; Rivastigmine Nursing Home Study Team. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3: 137-48.
37. Howard RJ, Juszczak E, Ballard CG et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-92.
38. Cummings JL, Schneider E, Tariot PN, Graham SM; Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67: 57-63.
39. Cummings JL, Mackell J, Kaufer D. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Alzheimers Demen 2008; 4: 49-60.
40. Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008; 300: 1774-83.
41. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; 8: CD004514.
42. Scheider LS, DeKosky ST, Farlow MR et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. Curr Alzheimer Res 2005; 2: 541-51.
43. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009; 1: CD003120.
44. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 33: 1216-22.
45. Mowla A, Mosavinasab M, Haghshenas H, Haghighi AB. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2007; 5: 484-7.
46. Lyketsos CG, DelCampo L, Steinberg M et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737-46.
47. Lyketsos CG, Szekely CA, Mielke MM, Rosenberg PB, Zandi PP. Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr 2008; 5: 871-89.